Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant

Nirmatrelvir boosted with Ritonavir is the recommended and preferred treatment for COVID-19. Because real-world evidence of Nirmatrelvir’s antiviral activity against the Omicron variation is minimal, our study focuses on recent papers suggesting the use of Ritonavir-boosted Nirmatrelvir in the real...

Descripción completa

Detalles Bibliográficos
Autores principales: Imran, Laiba, Zubair, Rooja, Mughal, Sanila, Shakeel, Ramsha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949877/
https://www.ncbi.nlm.nih.gov/pubmed/36845759
http://dx.doi.org/10.1097/MS9.0000000000000169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949877/
https://www.ncbi.nlm.nih.gov/pubmed/36845759
http://dx.doi.org/10.1097/MS9.0000000000000169

Ejemplares similares